Rapid fluorescence immunoassay of benzo [a] pyrene in mainstream cigarette smoke based on a dual-functional antibody–DNA conjugate

Benzo[a]pyrene (BaP) is considered as one of the most carcinogenic pollutants in cigarette smoke. The development of simple and sensitive BaP screening methods can help assess the risk of cigarette exposure to the human body rapidly. In this report, a rapid fluorescence immunoassay (RFIA) method for the detection of BaP is proposed, the core of which is the synthesis of bifunctional covalent antibody–DNA conjugates for target recognition and signal amplification. Based on the optimization of the SYBR Green I and PAH–BSA concentrations, as well as DNA–antibody immune complex's dilution in the RFIA system, a serial dilution of BaP was tested with this method. The results showed that the linear working range of the RFIA for BaP is 0.46 to 333 ng mL−1, which is much wider than traditional ELISA. The detection limit was 0.32 ng mL−1, which was more sensitive than other methods such as the redox-labeled electrochemical immunoassay method and the competitive piezoelectric biosensor. Then the cross-reactions (CR) of other PAHs in cigarette smoke were evaluated using this RFIA and found that the cross-reactions of naphthalene, anthracene, and pyrene were very low (<1%). The cross-reaction in this RFIA system can be reduced by improving the specificity of the antibody. To the best of our knowledge, this is the first time that the BaP in mainstream cigarette smoke was tested; the RFIA demonstrates fast and simple experimental manipulations and better working curves and sensitivity.